Nitrogen-containing bisphosphonate incadronate augments the inhibitory effect of farnesyl transferase inhibitor tipifarnib on the growth of fresh and cloned myeloma cells in vitro

Leukemia and Lymphoma

Volumn 46, Issue 11, 2005, Pages 1619-1625

  Ochiai, Naoya ^a   Yamada, Noriko ^a   Uchida, Ryo ^a   Fuchida, Shin Ichi ^a   Okano, Akira ^a   Okamoto, Masashi ^a   Ashihara, Eishi ^a   Inaba, Tohru ^a   Shimazaki, Chihiro ^a  

^a KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

Author keywords

Farnesyl transferase inhibitor; Incadronate; Multiple myeloma; Tipifarnib

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; GUANINE NUCLEOTIDE BINDING PROTEIN; INCADRONIC ACID; NITROGEN DERIVATIVE; PROTEIN FARNESYLTRANSFERASE INHIBITOR; RAS PROTEIN; TIPIFARNIB;

ADULT; AGED; ARTICLE; CELL CLONE; CELL GROWTH; CONTROLLED STUDY; DRUG MECHANISM; DRUG POTENTIATION; FEMALE; GENE MUTATION; GROWTH INHIBITION; HUMAN; HUMAN CELL; IN VITRO STUDY; MALE; MULTIPLE MYELOMA; MYELOMA CELL; ONCOGENE RAS; PRIORITY JOURNAL; PROTEIN PROCESSING;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; CELL PROLIFERATION; DIPHOSPHONATES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; FARNESYLTRANSTRANSFERASE; HUMANS; MULTIPLE MYELOMA; QUINOLONES; TUMOR CELLS, CULTURED;

EID: 28244449616     PISSN: 10428194     EISSN: None     Source Type: Journal    
DOI: 10.1080/10428190500221223     Document Type: Article

References (35)

1. Rowinski EK, Windle JJ, von Hoff DD. Ras protein farnesyltransferase: A strategic target for anticancer therapeutic development. J Clin Oncol 1999;17:3631-3652.
2. Beaupre DM, Kurzrock R. Ras and leukemia: from basic mechanisms to gene-detected therapy. J Clin Oncol 1999;17:1071-1079.
3. Reuter CWM, Morgan MA, Bergmann L. Targeting the ras signaling pathway: a rational, mechanism-based treatment for hematologic malignancies? Blood 2000;96:1655-1669.
4. Corradini P, Ladetto M, Voena C, Palumbo A, Inghirami G, Knowles DM, et al. Mutational activation of N-and K-ras oncogenes in plasma cell dyscrasias. Blood 1993;81:2708-2713.
5. Paquette RL, Berenson J, Lichtenstein A, McCormic F, Koeffler HP. Oncogenes in multiple myeloma: point mutation of N-ras. Oncogene 1990;5:1659-1663.
6. Liu P, Leong T, Quam L, Billadeau D, Kay NE, Greipp P, et al. Activating mutations of N- and K-ras in multiple myeloma show different clinical associations: analysis of the Eastern Cooperative Oncology Group phase III trial. Blood 1996;88:2699-2706.
7. Kalakonda N, Rothwell DG, Scarffe JH, Norton JD. Detection of N-ras codon 61 mutations in subpopulations of tumor cells in multiple myeloma. Blood 2001;98:1555-1560.
8. Karp JE. Farnesyl protein transferase inhibitors as targeted therapies for hematologic malignancies. Semin Hematol 2001; 38(suppl 7):16-23.
9. End DW, Smets G, Todd AV, Applegate TL, Fuery CJ, Angibaud P, et al. Characterization of the antitumor effect of the selective farnesyl transferase inhibitor R115777 in vivo and in vitro. Cancer Res 2001;61:131-137.
10. Gouill SL, Pellat-Deceunynck C, Harroseau J-L, Rapp M-J, Robillard N, Bataille R, et al. Farnesyl transferase inhibitor R115777 induces apoptosis of human myeloma cells. Leukemia 2002;16:1664-1667.
11. Ochiai N, Uchida R, Fuchida S, Okano A, Okamoto M, Ashihara E, et al. Effect of farnesyl transferase inhibitor R115777 on the growth of fresh and cloned myeloma cells in vitro. Blood 2003;102:3349-3353.
12. Zujewski J, Horak ID, Bol CJ, Woestenborghs R, Bowden C, End DW, et al. Phase 1 and pharmacokinetic study of farnesyl protein transferase inhibitor R115777 in advanced cancer. J Clin Oncol 2000;18:927-941.
13. Karp JE Lancet JE Kaufmann SH, End DW, Wright JJ, Bol K, et al. Clinical and biologic activity of the farnesyl transferase inhibitor R115777 in adults with refractory and relapsed acute leukemias: a phase 1 clinical-laboratory correlative trial. Blood 2001;97:3361-3369.
14. Alsina M, Fonseca R, Wilson EF, Belle AN, Gerbino E, Price-Troska T, et al. The Farnesyltransferase inhibitor tipifarnib is well tolerated, induces stabilization of disease and inhibits farnesylation and oncogenic/tumor survival pathways in patients with advanced multiple myeloma. Blood 2004;103:3271-3277.
15. Cortes J, Albitar M, Thomas D, Giles F, Kurzrock R, Thibault A, et al. Efficacy of the farnesyl transferase inhibitor, Zarnestra™ (R115777), in chronic myeloid leukemia and other hematologic malignancies. Blood 2003;101:1692-1697.
16. Santucci R, Mackley PA, Sebti S, Alsina M. Farnesyltransferase inhibitors and their role in the treatment of multiple myeloma. Cancer Control 2003;10:384-387.
17. Kohl NE, Wilson FR, Mosser SD, Giuliani E, deSolms SJ, Conner MW, et al. Protein farnesyltransferase inhibitors block the growth of ras-dependent tumors in nude mice. Proc Natl Acad Sci USA 1994;91:9141-9145.
18. V12 proteins to farnesyltransferase inhibitors in Rat1 cells. Proc Natl Acad Sci USA 1996;93:4454-4458.
19. Rowell CA, Kowalczyk JJ, Lewis MD, Garcia AM. Direct demonstration of geranylgeranylation and farnesylation of Ki-Ras in vivo. J Biol Chem 1997;272:14093-14097.
20. Whyte DB, Kirschmeimer P, Hockenberry TN, Nunez-Oliva I, James L, Catino JJ, et al. K- and N-Ras are geranylgeranylated in cells treated with farnesyl protein transferase inhibitors. J Biol Chem 1997;272:14459-14464.
21. Feldkamp MM, Lau N, Roncari L, Guha A. Isotype-specific Ras GTP-levels predict the efficacy of farnesyl transferase inhibitors against human astrocytomas regardless of Ras mutational status. Cancer Res 2001;61:4425-4431.
22. Beaupre DM, Cepero E, Obeng EA, Boise LH, Lichtenheld MG. R115777 induces Ras-independent apoptosis of myeloma cells via multiple intrinsic pathways. Mol Cancer Ther 2004;3:179-186.
23. Berenson JR, Lightenstein A, Porter L, Domopoulos MA, Bordoni R, George S, et al. Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. N Engl J Med 1996;334:488-493.
24. Shipman CM, Croucher PI, Russell RGG, Helfrich MH, Rogers MJ. The bisphosphonate incadronate (YM175) causes apoptosis of human myeloma cells in vitro by inhibiting the mevalonate pathway. Cancer Res 1998;61:5294-5297.
25. Luckman SP, Hughes DE, Coxon FP, Russell RGG, Rogers MJ. Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras. J Bone Miner Res 1998;13:581-589.
26. Takahashi R, Shimazaki C, Inaba T, Okano A, Hatsuse M, Okamoto A, et al. A newly developed bisphosphonate, YM529, is a potent apoptosis inducer of human myeloma cells. Leukemia Res 2001;25:77-83.
27. Goldstein JL, Brown MS. Regulation of the mevalonate pathway. Nature 1990;343:425-430.
28. Jego G, Robillard N, Puthier D, Amiot M, Accard F, Pineau D, et al. Reactive plasmacytoses are expansions of plasma-blasts retaining the capacity to differentiate into plasma cells. Blood 1999;94:701-712.
29. Herault O, Colombat P, Domenech J, Degenne M, Bremond J-L, Sensebe L, et al. A rapid single-laser flow cytometric method for discrimination of early apoptotic cells in a heterogenous cell population. Br J Hematol 1999;104: 530-537.
30. 3H]-thymidine incorporation assay. J Immunol Methods 1994;170:211-224.
31. Peters DG, Hoover RR, Gerlach MJ, Koh EY, Zhang H, Choe K, et al. Activity of the farnesyl protein transferase inhibitor SCH66336 against BCR/ABL-induced murine leukemia and primary cells from patients with chronic myeloid leukemia. Blood 2001;97:1404-1412.
32. Sepp-Lorenzino L, Ma Z, Rands E, Kohl NE, Gibbs JB, Oliff A, et al. A peptidomimetic inhibitor of farnesyl protein transferase blocks the anchorange-dependent and -independent growth of human tumor cell lines. Cancer Res 1995;15:5302-5309.
33. Mazet JL, Padieu M, Osman H, Maume G, Mailliet P, Dereu N, et al. Combination of the novel farnesyltransferase inhibitor RPR130401 and the geranylgeranyltransferase-1 inhibitor GGTI-289 disrupts MAP kinase activationin and G1-S transition in K-Ras-overexpressing transformed adenocortical cells. FEBS Letters 1999;460:235-240.
34. Hu L, Shi Y, Hsu J-H, Gera J, Van Ness B, Lichtenstein A. Downstream effectors of oncogenic Ras in multiple myeloma cells. Blood 2003;101:3126-3135.
35. Zhan F, Hardin J, Kordsmeier B, Bumm K, Zheng M, Tian E, et al. Global gene expression profiling of multiple myeloma, monoclonal gammopathy of undetermined significance, and normal bone marrow plasma cells. Blood 2002;99:1745-1757.